Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Opioid REMS Prescriber Education Should Be Mandatory, FDA Panel Says

This article was originally published in The Pink Sheet Daily

Executive Summary

This time, the agency may be ready to agree with its advisory committee.


Related Content

Opioids May All Require Mandatory Education As US FDA Expands REMS To Immediate-Release Formulations
Opioid Approval Standards Not Up For Debate, FDA Tells Advisory Cmte.
Teva's Opioid Vantrela: Conflicting Data On Oral Abuse Deterrence
Fluoroquinolones Get New Safety Labeling, But Not A REMS
Opioids: FDA Asks If Abuse-Deterrence Incentives Are In Line
Restrictive REMS Is Least Favored Path For Opioid Prescriber Education
Recent And Upcoming FDA Advisory Committee Meetings
KemPharm's Opioid Apadaz Will Likely Miss Out On Abuse Deterrence Claim
FDA's Opioid REMS Review Puts Brakes On Mandatory Education Push
FDA Opioid REMS Proposal Leaves Advisory Panel Wanting More - i.e. Mandatory Training